Jeremy Chataway

Aug 9, 2023 | journals.sagepub.com | Maria Pia Sormani |Jeremy Chataway |Ruth Ann Marrie

IntroductionOutcomes in multiple sclerosis (MS) are well recognized to be heterogeneous. This heterogeneity may also extend to therapeutic responses and adverse effects and can be accounted for by multiple factors including genetic differences, as well as age, sex, liver or renal function, health behaviors, and disease severity.1 For example, genetic variation influences the expression of thiopurine S-methyltransferase (TPMT) enzyme.

Aug 9, 2023 | journals.sagepub.com | Ruth Ann Marrie |Jeremy Chataway |Barbara E. Bierer |Marcia Finlayson

AbstractBackground:Demographic characteristics, social determinants of health (SDoH), health inequities, and health disparities substantially influence the general and disease-specific health outcomes of people with multiple sclerosis (MS). Participants in clinical trials do not represent all people with MS treated in practice. Objective:To provide recommendations for enhancing diversity and inclusion in clinical trials in MS.